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ABSTRACS 
The objective of the present investigation was to study the effect of various water soluble carriers like 
urea, mannitol, PVP and PVP/VA-64 on in vitro dissolution of aceclofenac from solid dispersions. 
Aceclofenac binary solid dispersions (SD) with different drug loadings were prepared using the 
melting or fusion method. In vitro dissolution of pure drug, physical mixtures and solid dispersions 
were carried out. Solid dispersion of aceclofenac with all four carriers (urea, mannitol, PVP and 
PVP/VA-64) showed considerable increase in the dissolution rate in comparison with physical mixture 
and pure drug in 0.1 N HCl, pH1.2 and phosphate buffer, pH, 7.4. Solid dispersions containing PVP 
showed maximum dissolution rate in comparison to formulation containing urea, mannitol and 
PVP/VA-64. Amorphous nature of the drug in solid dispersion was confirmed by scanning electron 
microscopy and a decrease in enthalpy of drug melting in solid dispersion compared to the pure drug. 
FT-IR spectroscopy and differential scanning calorimetry studies indicated no interaction between 
aceclofenac and carriers in solid dispersions in solid state. Dissolution enhancement was attributed to 
decreased crystallinity of the drug and to the wetting, eutectic formation and solubilizing effect of the 
carrier from the solid dispersions of aceclofenac. In conclusion, dissolution of aceclofenac can be 
enhanced by the use of various hydrophilic carriers like urea, mannitol, PVP and PVP/VA-64. 
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INTRODUCCIÓN 
Up to 40 percent of new chemical entities discovered by the pharmaceutical industry today 
are poorly soluble or lipophilic compounds. The solubility issues complicating the delivery of 
these new drugs also affect the delivery of many existing drugs (1). Poorly water-soluble 
drugs show unpredictable absorption, since their bioavailability depends upon dissolution in 
the gastrointestinal tract (2–4). The dissolution characteristics of poorly soluble drugs can be 
enhanced by several methods (5–7). Solid dispersion is one of the effective and widely used 
techniques for dissolution enhancement (8). The two basic procedures used to prepare solid 
dispersions are the melting or fusion (9) and solvent evaporation (10) techniques. The increase 
in dissolution rate for solid dispersions can be attributed to a number of factors (11), which 
include reduction in particle size, absence of aggregation or agglomeration of fine crystallites 
of the drug, possible solubilization effect of the polymer, excellent wettability and 
dispersibility of the drug from solid dispersion and partial conversion of the drug into 
amorphous form. 
Aceclofenac (AF), 2-[(2,6-dichlorophenyl) amino] benzene acetic acid carboxymethyl 
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ester is a new generational non-steroidal anti-inflammatory drug showing effective anti-
inflammatory and analgesic properties and a good tolerability profile in a variety of painful 
conditions like ankylosing spondylitis, rheumatoid arthritis and osteoarthritis. Aceclofenac is 
very slightly soluble in water (12) and therefore an attempt has been made to prepare solid 
dispersions of aceclofenac using various hydrophillic carriers like urea, mannitol, 
polyvinylpyrrolidone (PVP) and polyvinyl pyrrolidone vinyl acetate-64 (PVP/VA-64) with an 
aim to improve its extent and rate of dissolution. Urea, mannitol, PVP and PVP/VA-64 are 
used for the preparation of solid dispersions. A particular advantage of such carriers for the 
formation of solid dispersions is having good solubility in many organic solvents. Additional 
attractive features of such carriers include improved compound wettability (13, 14, 15). 
Therefore, in the present study, urea, mannitol, PVP and PVP/VA-64 was chosen as suitable 
polymers for the preparation of solid dispersions.  
EXPERIMENTAL 
Materials 
Aceclofenac was obtained as a gift sample from Ipca Laboratories, Mumbai, India. 
PVP/VA-64 were purchased from BASF, Ludwigshafen, Germany. Polyvinylpyrrolidone 
(PVP), mannitol, urea were obtained from Merck (Germany). 
Preparation of Solid Dispersions of Aceclofenac 
Solid dispersions of AF were prepared with urea, mannitol, PVP and PVP/VA-64 in 
different ratios such as 1:0.5, 1:1 and 1:2 by weight basis using melting or fusion method. 
Weighed quantities of carrier (urea, mannitol, PVP and PVP/VA-64) and AF were thoroughly 
mixed and melted on hot plate with constant stirring to obtain a uniform melt. The melt was 
shock cooled on an ice cooled stainless steel plate. The solid mass was removed from the 
stainless steel plate, powdered and kept in a desiccator for two days. The powder was passed 
through sieve #100 and stored in closed airtight container (16).  
Preparation of Physical mixtures:  
The physical mixtures were prepared by mixing pre-weighed amounts of mesh. No 100-
sieve fractions of aceclofenac and carriers in the same proportions as used in solid dispersions 
(16). 
Characterisation  
Percent Yield  
The percent yield of SDs was calculated on the basis of dry weight (drug and carriers) 
and the final weight of SDs obtained (17, 18). 
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Average Particle Size  
The SDs were dispersed in liquid paraffin and mounted on slides.  Particle size of 200 
particles was measured using calibrated stage micrometer and ocular micrometer. From 
the data the average particle size was calculated (19).  
Wettability Study  
Powdered mixture of SDs (300 mg) was placed in a sintered glass funnel with 33 mm 
internal diameter. The funnel was plunged into beaker containing water such that the 
surface of water in the beaker was at the same level as the powder or granules in the 
funnel. Methylene blue powder (10 mg) was layered uniformly on the surface of the 
powder or granules in the funnel. The time required for wetting of methylene blue 
powder was measured. The mean of three observations was used for drawing the 
conclusions (20). 
Hygroscopic Studies 
One hundred mg each of SDs (w1) was placed on a watch glass and exposed to 
ambient atmospheric conditions (70±5% RH, 30±2°C) and saturation humidity 
conditions (99±1% RH, 30±2°C) for 2 days. The substance was weighed again (w2).  
The gain in the weight was determined and the percentage moisture gained was 
calculated. (21). 
Drug Content  
The SDs (100mg) were accurately weighed and dissolved separately in 100ml of 
20%v/v acetic acid. The solution was suitably diluted and the absorbance was measured 
at 275 nm .  Drug content was calculated using the regression equation (17). 
Scanning Electron Microscopy  
 Scanning Electron Microscopy (SEM) was carried out for 1:1 SDs. The surface 
morphology of the selected binary systems was studied using a Phillips 1500, scanning 
electron microscope. The powders were previously fixed on a brass stub using double 
sided adhesive tape and then were made electrically conductive by coating in vaccum, 
with a thin layer of gold (approximately 300 Å), for 30s and at 30 W. The micrographs 
were taken at an excitation voltage of 15 KV and a magnification of 750 or 5000 X (22, 23 
). 
Fourier Transformed Infrared Spectroscopic Studies  
FTIR spectral studies were carried out for pure drug, freshly prepared and six months 
old 1:1 SDs and individual substances to check the compatibility between drug and 
carriers using Shimadzu FTIR-8400S Fourier transform infrared spectrophotometer. 
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Interaction between the components, if any, was indicated by either producing additional 
peaks or absence of the characteristic peaks corresponding to the drug and carrier (24).   
Differential Scanning Calorimetric Studies  
DSC studies were carried out for pure drug, freshly prepared and six months old 1:1 
SDs, CPs and molecular inclusion complexes. All dynamic DSC studies were carried out 
on a calibrated Shimadzu DSC-50 Thermal Analyzer. Calorimetric measurements were 
made with empty cell (high purity alpha alumina discs as reference). The dynamic scans 
were taken in nitrogen atmosphere at the heating rate of 10°C/minute. Interaction 
between the drug and polymer, if any, was indicated either by a shift in the peak or 
presence of additional peaks at temperatures other than those corresponding to the drug 
and carrier (22, 25). 
In Vitro Release Studies  
In vitro release studies were carried out using basket type USP XXII dissolution test 
apparatus (26). Release studies were carried separately for pure drug, physical mixtures, SDs 
for 2h in 900 ml of 0.1 N hydrochloric acid solution, pH 1.2 and phosphate buffer, pH 7.4 
separately, with a stirring speed of 50 rpm at a temperature of 37±0.5 °C. Five ml aliquots of 
dissolution medium were withdrawn at an interval of 5 minutes for first 15 minutes and then 
15 minutes intervals, for rest of the two-hour study Absorbance of the suitably diluted 
solutions was measured at 275 nm The drug content was calculated using regression equation. 
The dissolution experiments were conducted in triplicate (27, 28). 
Kinetic Analysis of Drug Release 
The dissolution profiles of all the solid dispersions were subjected to the kinetic analysis to 
establish the drug-release mechanism. The release data were fitted to zero order, first order, 
matrix (Higuchi model), and Hixson-Crowell equations to ascertain the kinetic modeling of 
drug release (29).   
RESULTS AND DISCUSSION 
All the SDs prepared were found to be fine and free flowing powders. Percentage yield 
ranged from 84.2 to 96.5% (Table 1). Low coefficient of variance (CV) values (< 1.0 %) in 
percentage yield indicates the reproducibility of the technique employed for the preparation of 
SDs. Average particle size was found to be within the range of 51.11µm to 73.2µm (Table 1). 
This narrow range of particle size was satisfactory from the point of improving the aqueous 
solubility.  
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 Table 1:  Physical characteristics of solid dispersions of aceclofenac. 
Carrier Product 
Drug : 
carrie
r 
Percen
t yield 
Particl
e size 
range 
(µm) 
Averag
e 
particle 
size     
(µm) 
Drug 
conten
t     
(mg/10
0 mg) 
Percen
t drug 
content 
Wettin
g Time 
(sec) 
AF-U-
SD3 
1 : 2 
87.3 
(0.76) 
6.1-
154.3 
73.2 
(0.94) 
31.5 
(33)* 
95.4 
(0.96) 
17.11 
(0.21) 
AF -U-
SD2 
1 : 1 
84.2 
(0.96) 
5.5- 
152.1 
 
56.68 
(0.91) 
48.5 
(50)* 
97.0 
(0.85) 
19.23 
(0.17) 
Urea 
AF -U-
SD1 
1 : 0.5 
96.5 
(0.91) 
6.3- 
151.5 
64.15 
(0.93) 
63.6 
(66.7)* 
95.3 
(0.81) 
21.41 
(0.19) 
AF -M-
SD3 
1 : 2 
89.4 
(0.81) 
7.2- 
134.2 
59.15 
(0.77) 
30.0 
(33)* 
90.9 
(0.96) 
14.13 
(0.23) 
AF -M-
SD2 
1 : 1 
90.5 
(0.94) 
6.9- 
152.3 
65.16 
(0.81) 
44.8 
(50.0)* 
89.6 
(0.93) 
17.32 
(0.27) 
Mannitol 
AF -M-
SD1 
1 : 0.5 
86.5 
(0.74) 
7.1-
142.8 
62.13 
(0.82) 
65.2 
(66.7)* 
97.7 
(0.95) 
18.64 
(0.23) 
AF-
PVP-
SD3 
1 : 2 
89.4 
(0.82) 
7.5-
153.2 
61.12 
(0.85) 
31.6 
(33)* 
95.7 
(0.76) 
23.12 
(0.15) 
AF-
PVP-
SD2 
1 : 1 
90.5 
(0.96) 
6.9-
143.2 
60.54 
(0.98) 
48.4 
(50)* 
96.8 
(0.85) 
22.16 
(0.18) 
 
PVP 
 
 
 AF-
PVP-
SD1 
1 : 0.5 
94.3 
(0.93) 
7.1-
143.6 
53.21 
(0.99) 
65.9 
(66.7)* 
98.8 
(0.87) 
24.21 
(0.28) 
AF-
PVP/VA-
SD3 
1 : 2 
94.1 
(0.87) 
6.9-
150.2 
67.43 
(0.79) 
31.9 
(33)* 
96.6 
(0.95) 
20.13 
(0.21) 
AF-
PVP/VA-
SD2 
1 : 1 
89.5 
(0.81) 
7.0-
148.4 
63.21 
(0.83) 
49.3 
(50)* 
98.6 
(0.91) 
19.11 
(0.15) 
 
PVP/VA-
64 
 
 
 AF-
PVP/VA-
SD1 
1 : 0.5 
92.1 
(0.91) 
6.3-
155.7 
51.11 
(0.94) 
63.5 
(66.7)* 
95.2 
(0.88) 
18.32 
(0.12) 
AF: aceclofenac; M: mannitol; PVP: polyvinyl pyrrolidone; PVP/VA-64: polyvinyl pyrrolidone vinyl acetate; 
SD: solid dispersion; U: urea. Values in parenthesis indicates the standard deviation 
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(n=3) and values given in the parenthesis marked with * indicates theoretical values of drug content. 
 
 
Table 2: Determination of hygroscopicity of solid dispersions of aceclofenac. 
Ambient conditions (70 ± 5% 
RH,  
30 ± 2 °C) 
Saturation humidity 
conditions 
(99±  2% RH,  
30 ± 2°C) Formulat
ion code 
Drug: 
Carrie
r 
Initial 
weight 
(mg) Final 
weight 
(mg) 
Percent weight 
gained        (mg) 
Final 
weight 
(mg) 
Percent 
weight gained 
(mg) 
AF 
Pure 
drug 
100 100.7 0.7 (0.11) 101.3 1.3 (0.34) 
AF -U-
SD3 
1 : 2 100 119.3 19.3 (0.07) 163.6 63.6 (0.32) 
AF -U-
SD2 
1 : 1 100 108.3 8.3 (0.13) 140.0 40.0 (0.29) 
AF -U-
SD1 
1 : 0.5 100 107.5 7.5 (0.09) 120.5 20.5 (0.33) 
AF -M-
SD3 
1 : 2 100 107.3 7.3 (0.11) 112.4 12.4 (0.31) 
AF -M-
SD2 
1 : 1 100 102.1 2.1 (0.12) 109.1 9.1 (0.29) 
AF -M-
SD1 
1 : 0.5 100 100.5 0.5 (0.05) 102.0 2.0 (0.31) 
AF-PVP-
SD3 
1 : 2 100 112.2 12.2 (0.07) 145.4 45.4 (0.34) 
AF-PVP-
SD 2 
1 : 1 100 109.6 9.6 (0.08) 139.7 39.7 (0.30) 
AF-PVP-
SD1 
1 : 0.5 100 107.5 7.5 (0.13) 132.3 32.3 (0.28) 
AF-
PVP/VA-
SD3 
1 : 2 100 107.3 7.3 (0.13) 133.2 33.2 (0.32) 
AF-
PVP/VA-
SD2 
1 : 1 100 105.2 5.2 (0.17) 127.1 27.1 (0.29) 
AF-
PVP/VA-
SD1 
1 : 0.5 100 103.7 3.7 (0.05) 121.2 21.2 (0.31) 
AF: aceclofenac; M: mannitol; PVP: polyvinyl pyrrolidone; PVP/VA-64: polyvinyl pyrrolidone vinyl acetate; 
SD: solid dispersion; U: urea. Values in parenthesis indicates the standard deviation (n=3) 
The wetting time ranged from 14.13 to 24.21 sec .The maximum wetting time was 
observed with AF-PVP-SD1 (24.21 sec). The percentage entrapment of the drug in SDs was 
found to be approximately nearer to the theoretical values. Low value for CV (<1.0) indicates 
uniformity of drug content in the product. The obtained results implied that the drug remained 
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stable during preparation. 
Hygroscopic Studies  
The hygroscopicity of binary system containing AF-PVP was found to be more in 
comparison with other carriers under ambient as well as saturation humidity conditions. 
Similar results were reported by Sethia and Squilante (30) with carbamazepine and Martinez-
ohariz et al. (31) with diflunisal. At saturation humidity conditions the weight gain was higher, 
compared to ambient conditions. SDs containing urea and PVP absorbed more moisture 
compared to SDs containing mannitol and PVP/VA-64. 
Scanning Electron Microscopy  
AF appeared as irregular shaped crystals and β-CD has shown a parallelogram shape. The 
original morphology of all other binary systems (SDs, CPs and molecular inclusion 
complexes) had disappeared and it was not possible to differentiate between the two 
components. All the binary systems appeared as agglomerates exhibiting the presence of a 
homogeneous solid phase of amorphous nature. Existence of a single phase is also responsible 
for the enhanced drug dissolution in comparison to pure AF (Figure 1). 
Figure 1 :Scanning electron photomicrographs of aceclofenac (A); aceclofenac-urea (1:2) solid 
dispersion (B); aceclofenac-mannitol (1:2) solid dispersion (C); aceclofenac-PVP (1:2) solid 
dispersion (D); aceclofenac-PVP/VA-64 (1:2) solid dispersion (E) 
 
Fourier Transformed Infrared Spectroscopic Studies 
All the characteristic bands of AF were observed in the binary mixtures are shown in Table 
3. Broadening of bands was observed to a large extent. The characteristic bands of urea (1150, 
1455 and 1680 cm-1), mannitol (3300, 1421, 1083 and 1019 cm-1), PVP (2970, 1452, 1417, 
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1716 and 1270 cm-1), PVP/VA-64 (2970, 1452, 1417, 1716 and 1270 cm-1) and β-CD (3305, 
1420, 1460 and 1083 cm-1) were also observed. The FTIR spectra of physical mixtures, solid 
dispersions, coprecipitates and β-CD complexes indicate reduction in the intensity of several 
peaks like O-H (s) and C-H (s). The absence of any significant change in the IR spectral 
pattern in the formulations containing the drug and carriers indicated the absence of 
interaction between the drug and carriers employed for the solubility enhancement (Figure 2, 
3, 4 and 5).  
Table 3: FTIR characteristic bands of aceclofenac in solid dispersions. 
 
Assignment of 
bands 
Absorption 
band for 
aceclofenac 
cm
-1 
Absorption 
band for 
aceclofenac 
in urea, 
cm
-1 
Absorption 
band for 
aceclofenac 
in mannitol, 
cm
-1 
Absorption 
band for 
aceclofenac 
in PVP , 
cm
-1 
Absorption 
band for 
aceclofenac 
in PVP/VA-
64, cm
-1 
N-H (s) 3340 3330 3335 3319.26 3319.26 
O-H (s) 3100 3120 3100 3070.46 3070.46 
Ar C-H (s) 3050 3045 3060 3028.03 3028.03 
C=O (s) 1730 1710 1722 1716.53 1716.53 
Aromatic ring 1580 1530 1520 1580 1582 
C-O-C (s) 1250 1262 1210 1255.57 1255.57 
C-Cl (s) 750 730 760 750.26 750.26 
 
Figure 2: FTIR spectra of aceclofenac, physical mixtures and different solid dispersion systems with 
urea. (A) AF; (B) AF-U (PM) 1:0.5; (C) AF-U (SD) 1:0.5; (D) AF-U (PM) 1:1; (E) AF-
U (SD) 1:1; (F) AF-U (PM) 1:2; (G) AF-U (PM) 1:2 (SD). AF=aceclofenac; PM= 
physical mixture; SD= solid dispersion; U=urea. 
A
B
D
F
C
E
G
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Figure 3: FTIR spectra of aceclofenac, physical mixtures and different solid dispersion systems with 
mannitol. (A) AF-M (PM) 1:0.5; (B) AF-M (SD) 1:0.5; (C) AF-M (PM) 1:1; (D) AF-M 
(SD) 1:1; (E) AF-M (PM) 1:2; (F)AF-M (PM) 1:2 (SD). AF=aceclofenac; M= mannitol; 
PM= physical mixture; SD= solid dispersion. 
(A) (B)
(C) (D)
(E) (F)
 
Figure 4: FTIR spectra of aceclofenac, physical mixtures and different solid dispersion systems with 
PVP. (A) AF-PVP (PM) 1:0.5; (B) AF-PVP (SD) 1:0.5; (C) AF-PVP (PM) 1:1; (D) AF-
PVP (SD) 1:1; (E) AF-PVP (PM) 1:2; (F)AF-PVP (PM) 1:2 (SD). AF=aceclofenac; PM= 
physical mixture; PVP= polyvinyl pyrrolidone; SD= solid dispersion. 
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(A) (B)
(C) (D)
(E) (F)
 
 
 
 
Figure 5: FTIR spectra of aceclofenac, physical mixtures and different solid dispersion systems with 
PVP/VA-64. (A) AF-PVP/VA-64 (PM) 1:0.5; (B) AF- PVP/VA-64 (SD) 1:0.5; (C) AF- PVP/VA-64 
(PM) 1:1; (D) AF- PVP/VA-64 (SD) 1:1; (E) AF-PVP/VA-64 (PM) 1:2; (F)AF-PVP/VA-64 (PM) 1:2 
(SD). AF=aceclofenac; PM= physical mixture; PVP/VA-64= polyvinyl pyrrolidone vinyl acetate; SD= 
solid dispersion. 
(A) (B)
(C) (D)
(E) (F)
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Differential Scanning Calorimetric Studies 
The DSC thermograms of AF, urea, mannitol, PVP, PVPVA, various physical mixtures 
and solid dispersion are given in Figure 6, 7, 8 and 9. The pure AF exhibited endothermic 
peaks at 152.48°C which represents melting of AF and in accordance with the literature value 
(12). Urea, Mannitol, PVP and PVPVA depicted endotherms at 132.66 °C, 165.67 °C, 102 °C 
and 72.8 °C, respectively which corresponded to their respective melting points.  
The DSC curve of AF with various carriers physical mixtures show peaks resulting from 
the superposition of their separated component DSC curves. The drug endothermic peak was 
suppressed in the thermograms of the solid dispersions and coprecipitates suggesting that the 
drug was able to dissolve partially in the carrier to form a solid-solid solution. The appearance 
of low intensity endothermic peak also indicated some of the drug still managed to crystallize 
out from the matrix of carrier. These phenomena could also be attributed to the amorphous 
form of the drug in prepared solid dispersions and coprecipitates.  
DSC thermograms indicate the existence of the new solid phase and confirm FTIR spectral 
data concerning the presence of AF in an amorphous and homogenously dispersed state in 
carriers employed. The DSC further supported that AF was compatible with urea, mannitol, 
PVP and PVPVA under study. No additional or shift in endothermic peaks were observed 
which indicated the compatibility between the drug and carriers. The findings indicated that 
the drug was stable in SDs prepared freshly and after 6 months storage. 
Figure 6: DSC thermogram of  (A) AF; (B) Urea; (C) AF-U 1:0.5 (PM); (D) AF-U 
1:0.5 (SD); (E) AF-U 1:1 (PM); (F) AF-U 1:1 (SD); (G) AF-U 1:2 (PM); (H) AF-U 1:2 (SD). AF= 
aceclofenac; PM= physical mixture; SD= solid dispersion; U= Urea. 
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(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: DSC thermogram of  (A) AF; (B) Mannitol; (C) AF-M 1:0.5 (PM); (D) AF-M 1:0.5 
(SD); (E) AF-M 1:1 (PM); (F) AF-M 1:1 (SD); (G) AF-M 1:2 (PM); (H) AF-M 1:2 (SD).  AF= 
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aceclofenac; M= mannitol; PM= physical mixture; SD= solid dispersion. 
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
 
 Figure 8: DSC thermogram of (A) AF; (B) PVP; (C) AF-PVP 1:0.5 (PM); (D) AF-PVP 1:0.5 (SD); 
(E) AF-PVP 1:1 (PM); (F) AF-PVP 1:1 (SD); (G) AF-PVP 1:2 (PM); (H) AF-PVP 1:2 (SD).  
AF= aceclofenac; PM= physical mixture; PVP= polyvinylpyrrolidone; SD= solid 
dispersion. 
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
 
 
 
 
 
Figure 9: DSC thermogram of  (A) AF; (B) PVP/VA; (C) AF-PVP/VA 1:0.5 (PM); (D) AF-PVP/VA 
1:0.5 (SD); (E) AF-PVP/VA 1:1 (PM); (F) AF-PVP/VA 1:1 (SD); (G) AF-PVP/VA 1:2 (PM); (H) AF-
PVP/VA 1:2 (SD).  AF= aceclofenac; PM= physical mixture;  PVP/VA= polyvinylpyrrolidone vinyl 
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acetate 64; SD= solid dispersion. 
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
 
 
 
In Vitro Release Studies  
In both, 0.1N HCl (pH 1.2) and phosphate buffer (pH 7.4), the physical mixtures and SDs 
with all drug: carrier ratios exhibited faster dissolution rates than that of pure AF at all time 
points. The dissolution rate of SDs was faster as compared to their corresponding physical 
mixtures at all the time intervals (Table 4). With the increase in the proportion of carrier, rate 
of dissolution of SDs also increases. The SDs with 1:2 drug carrier ratio exhibited higher 
dissolution rate than others with lower carrier content (1:0.5 and 1:1). The order of dissolution 
shown by the SDs was found to be 1:2 > 1:1 > 1:0.5. Figure 10 and 11 depicts the 
comparative release from the selected solid dispersions in 0.1 N HCl, pH1.2 and phosphate 
buffer, pH, 7.4.  
 
 
 
 
 
 
Figure 10: In vitro dissolution profile of selected aceclofenac solid dispersions in 0.1N HCl, pH 1.2. 
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Figure 11: In vitro dissolution profile of selected aceclofenac solid dispersions in phosphate buffer, 
pH 7.4. 
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All the AF formulations showed a better dissolution profile in phosphate buffer, pH 7.4 in 
comparison to 0.1N HCl, pH 1.2. Similar results were reported by Soni et al. (32) in their 
saturation solubility studies of AF carried out in different dissolution media. Furthermore, this 
may be due to the weakly acidic nature of AF. With reference to pH-solubility profile, the 
dissolution rate of AF has been shown to increase on increasing pH of the medium (33). This 
supports higher drug release in phosphate buffer, pH 7.4 in the present study. 
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Table 4: In vitro dissolution profile of aceclofenac solid dispersions in 0.1 N HCl, pH 1.2 and 
phosphate buffer, pH 7.4. 
Percent drug released after 2 hr 
Composition Ratio 
0.1 N HCl, pH 1.2 Phosphate buffer, pH 7.4 
AF (Pure 
Drug) 
1:0 13.2 (0.91) 19.2 (1.02) 
1:0.5 29.3 (0.99) 46.3 (1.09) 
1:1 37.6 (1.09) 58.3 (1.17) 
 
AF-U 
1:2 48.9 (1.04) 67.3 (1.24) 
1:0.5 24.1 (0.99) 40.2 (1.15) 
1:1 31.2 (0.92) 51.2 (1.17) 
 
AF-M 
1:2 41.3 (0.93) 60.7 (1.16) 
1:0.5 50.6 (0.97) 52.3 (1.31) 
1:1 61.3 (0.99) 63.1 (1.27) 
 
AF-PVP 
1:2 65.3 (0.99) 73.9 (1.27) 
1:0.5 39.3 (1.22) 48.5 (1.21) 
1:1 52.4 (0.99) 60.3 (1.25) 
 
AF-PVP/VA 
1:2 60.7 (1.11) 68.5 (1.31) 
AF: aceclofenac; M: mannitol; PVP: polyvinyl pyrrolidone; PVP/VA-64: polyvinyl pyrrolidone vinyl acetate; 
SD: solid dispersion; U: urea. Values in parenthesis indicates the standard deviation (n=3) 
Formulations containing PVP showed maximum dissolution rate in comparison to 
formulation containing urea, mannitol and PVP/VA-64 which is in agreement with previous 
study on pizotifen malate with PVP as carrier (34). The present study revealed that 1:2 ratio of 
AF-PVP showed maximum drug release. Among all the solid dispersions, AF-PVP-SD3 
showed the maximum dissolution in 0.1N HCl, pH 1.2 (65.3±0.99%) and phosphate buffer 
pH 7.4 (73.9±1.27%) respectively. Due to the hydrophilic nature, PVP enhances the wetting 
of hydrophobic drugs in SDs. Since, wetting is prerequisite for dissolution, this effect 
contributed to the faster drug release as reported by Simonelli et al. (35) and Leuner and 
Dressman, (36).  Solubility could be enhanced further in presence of hydrogen bonding. 
Nevertheless, no hydrogen bonding interaction between PVP and AF could be detected in 
FTIR analysis. 
Another mechanism for this preferential enhancement of dissolution rate from SDs may be 
due to the formation of a eutectic mixture, or a solid solution (8). Such a solid solution cannot 
result from just physically mixing the two components and hence, physical mixture fails to 
increase the dissolution rate (37).Enhancement of dissolution rate from SDs can also be 
attributed to the amorphization of drug and the particle size reduction. The particle size 
reduction results in increased surface area available and thus, acceleration of dissolution (38). 
In SDs , the presence of the water soluble carrier results in improvement of wetting 
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characteristics of poorly soluble drug like AF (39). 
Kinetic Analysis of Drug Release  
The kinetics of in vitro release of the best formulations of AF (AF-U-SD3, AF-M-SD3, 
AF-PVP-SD3 and AF-PVP/VA-SD3) was carried out. The release of drug from all 
formulations was observed to follow the first order release kinetics, since the correlation 
coefficient (R2) for first order was higher in comparison to zero order release. The results 
were in agreement with the previous investigations performed by Goracinova et al. (40), 
Shivkumar et al. (41) and El-Maradny et al. (42).  
Table 5: Comparison of Orders of In Vitro dissolution profile of selected formulations of aceclofenac 
in 0.1N HCl, pH 1.2 and Phosphate buffer, pH 7.4 
Dissolution  
media Formulation
Regression equations
Zero order First order Higuchi Hixson Crowell
0.
1 
N
 H
C
l
pH
 1
.2
AF-U-SD3 
(1:2)
y = -0.3728t + 92.037
R² = 0.9191 
y = -0.0023t + 1.9685
R² = 0.9594
y = 4.5731√t - 1.7262
R² = 0.9805 
y = 0.0072x + 0.1172
R² = 0.9479
AF-M-SD3 
(1:2)
y = -0.3207t + 92.88
R² = 0.9105
y = -0.0018t + 1.9706
R² = 0.9476
y = 3.9489√t - 1.3091
R² = 0.9790
y = 0.0059x + 0.1074
R² = 0.9364
AF-PVP-
SD3 (1:2)
y = -0.4906t + 87.499
R² = 0.9049
y = -0.0036t + 1.9526
R² = 0.9692
y = 6.0758√t - 0.6094
R² = 0.9841 
y = 0.0106x + 0.1821
R² = 0.9525
AF-
PVP/VA-
SD3 (1:2)
y = -0.4537t + 92.838
R² = 0.9615
y = -0.003t + 1.9801
R² = 0.9761
y = 5.4214√t - 3.7315
R² = 0.9734
y = 0.0093x + 0.0884
R² = 0.9659
P
ho
sp
ha
te
 B
uf
fe
r
pH
 7
.4
AF-U-SD3 
(1:2)
y = -0.5233t + 87.55
R² = 0.8925 
y = -0.0039t + 1.952
R² = 0.961 
y = 6.5177√t - 1.7632
R² = 0.9816
y = 0.0114x + 0.1832
R² = 0.9416
AF-M-SD3 
(1:2)
y = -0.4923t + 91.291
R² = 0.9365
y = -0.0034t + 1.9705
R² = 0.9812 
y = 6.0099√t - 3.9081
R² = 0.9898
y = 0.0102x + 0.1189
R² = 0.9690
AF-PVP-
SD3 (1:2)
y = -0.5231t + 81.554
R² = 0.8453
y = -0.0043t + 1.9232
R² = 0.9503
y = 6.6242√t + 3.5547
R² = 0.9613
y = 0.0123x + 0.2856
R² = 0.9224
AF-
PVP/VA-
SD3 (1:2)
y = -0.4911t + 85.124
R² = 0.8699
y = -0.0037t + 1.9394
R² = 0.9515
y = 6.1611√t + 1.2593
R² = 0.9708
y = 0.0108x + 0.2259
R² = 0.9297
 
AF: aceclofenac; CP: coprecipitates; M: mannitol; PVP: polyvinyl pyrrolidone; PVP/VA-64: polyvinyl 
pyrrolidone vinyl acetate; SD: solid dispersion; U: urea. 
The data was further subjected to Higuchi equation and Hixson-Crowell cube root law. A 
higher correlation, as indicated by R2 was observed for the Higuchi matrix release kinetics in 
all the selected formulations suggesting the diffusion as a probable prominent mechanism of 
drug release (40, 41). In diffusion, the rate of dissolution of drug particles within the matrix 
must be much faster than that of the diffusion rate of drug leaving the matrix. The selection 
criteria (R2) and the equations best describing the kinetics of in vitro drug release is given in 
Table 5.  
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CONCLUSION 
This study clearly shows that addition of various hydrophillic carriers like urea, mannitol, 
PVP and PVP/VA-64 to aceclofenac improves its dissolution rate. Further, all the solid 
dispersions performed better than the corresponding physical mixtures. The present study also 
showed that urea, mannitol and PVP/VA-64 yielded solid dispersions with a less improved 
dissolution rate than PVP as carrier. DSC thermograms of physical mixture and solid 
dispersion indicated complete miscibility of the drug in melted carrier. Amorphous nature of 
the drug in solid dispersion was confirmed by scanning electron microscopy and a decrease in 
enthalpy of drug melting in solid dispersion compared to the pure drug. Results from FT-IR 
spectroscopy concluded that there was no well-defined interaction between aceclofenac and 
carriers employed in the preparation of solid dispersions. The solid dispersion of aceclofenac 
with PVP lends an ample credence for better therapeutic efficacy. 
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